Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021
Retrieved on:
Thursday, November 4, 2021
ERCB, Industry, Therapy, Barratt, COVID-19, SC, Immunoglobulin A, Immunoglobulin M, Risk, PK, Safety, Leicester, Nephrology, Biomarker, Plasma, Cell proliferation, Atrasentan, EDT, Forward-looking statement, United States Children's Bureau, HIV disease progression rates, LDHA, Conference, Research, GLOBE, Investor, PD, Michigan Medicine, Chronic kidney disease, University of Leicester, Doctor of Philosophy, Inflammation, European Renal Association – European Dialysis and Transplant Association, SEC, Pharmacokinetics, Proteinuria, University, Immunoglobulin G, Cohort, MD, AUC, Part, RNA, Tmax, Primary hyperoxaluria, ETA, IV, Incidence, Kidney, Cmax, B cell, Fibrosis, Nasdaq, UPCR, EGFR, Online gambling, Pharmaceutical industry
Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
Key Points:
- Blocking APRIL is a potentially disease-modifying approach to treating IgAN by reducing circulating levels of galactose-deficient IgA1 (Gd-IgA1).
- Patients in Cohort 1 received an intravenous (IV) dose of 450 mg of BION-1301 every two weeks.
- Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.
- BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy.